|
Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM. |
|
|
Consulting or Advisory Role - Novartis; Pfizer; Pfizer |
Speakers' Bureau - Exelixis; Ipsen; Medivation |
Research Funding - Acceleron Pharma (Inst); Alkermes (Inst); Argos Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Merck (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Prometheus (Inst) |
|
|
Employment - Bristol-Myers Squibb (I) |
Consulting or Advisory Role - Exelixis |
Speakers' Bureau - Bristol-Myers Squibb; Merck |
Research Funding - Argos Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Nektar (Inst); Prometheus (Inst) |
Travel, Accommodations, Expenses - Genentech/Roche; Genentech/Roche (I) |
|
|
Consulting or Advisory Role - AstraZeneca; Eisai; Roche |
Speakers' Bureau - AstraZeneca |
Research Funding - Acerta Pharma (Inst); ARIAD (Inst); AstraZeneca (Inst); Bayer (Inst); BIND Biosciences (Inst); BIND Biosciences (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Merck Sharp & Dohme (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); United Biosource Corporation (Inst) |
|
|
Consulting or Advisory Role - Alligator Bioscience; Eisai |
Speakers' Bureau - Bristol-Myers Squibb; Prometheus |
Research Funding - Bristol-Myers Squibb (Inst); Galectin Therapeutics (Inst); MedImmune (Inst); Prometheus (Inst); Viralytics (Inst) |
Patents, Royalties, Other Intellectual Property - Biomarkers for OX40 response (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MedImmune; Prometheus |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Cerulean Pharma; Clovis Oncology; Eisai; EMD Serono; Exelixis; Genentech/Roche; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer |
Research Funding - Amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst) |
|
|
Stock and Other Ownership Interests - Aethlon |
Honoraria - Best Doctors, Inc |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Pharmacyclics (Inst); SOTIO (Inst); US Oncology (Inst) |
Patents, Royalties, Other Intellectual Property - Patent pending on an immunotherapeutic |
Other Relationship - ABIM Subspecialty Board |
|
Kathleen Margaret Mahoney |
Consulting or Advisory Role - Jefferies |
Patents, Royalties, Other Intellectual Property - HHLA2 monoclonal antibodies to block the interaction with the receptor for potential therapeutics |
|
|
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Prometheus |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Merck |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Nektar (Inst); Viralytics (Inst) |
|
|
Honoraria - Astellas Pharma; Bayer; Boehringer Ingelheim; EMD Serono; Etubics; Ipsen; Lexicon; Merrimack; Novartis; Onyx; Regeneron; Roche/Genentech; Sanofi; Taiho Pharmaceutical |
Speakers' Bureau - Celgene; Genentech/Roche; Ipsen; Lexicon; Merck; Novartis; Taiho Pharmaceutical |
Research Funding - Advanced Accelerator Applications (Inst); AlphaVax (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lexicon (Inst); MedImmune (Inst); Merck (Inst); Onyx (Inst); Precision Biologics (Inst) |
|
|
Consulting or Advisory Role - Merck; Pfizer |
|
|
|
Honoraria - EMD Serono; SapVax |
Consulting or Advisory Role - EMD Serono; SapVax |
|
|
|
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb/Medarex; Eisai; Merck; Nektar; Prometheus; TRACON Pharma |
Speakers' Bureau - Exelixis; Prometheus |
Travel, Accommodations, Expenses - Exelixis; Prometheus |